"10.1371_journal.pone.0124710","plos one","2015-04-21T00:00:00Z","Joanne S Carpenter; Rébecca Robillard; Rico S C Lee; Daniel F Hermens; Sharon L Naismith; Django White; Bradley Whitwell; Elizabeth M Scott; Ian B Hickie","Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Camperdown, NSW, Australia","Conceived and designed the experiments: JSC RR DFH SLN EMS IBH. Performed the experiments: RR RSCL DW BW EMS. Analyzed the data: JSC. Contributed reagents/materials/analysis tools: RR RSCL DFH. Wrote the paper: JSC RR RSCL DFH SLN DW BW EMS IBH.","The authors have read the journal’s policy and have the following conflicts. DFH has received honoraria for educational seminars from Janssen-Cilag and Eli Lilly. EMS is the (unpaid) Clinical Director of Headspace Services at the BMRI, the (unpaid) Coordinator of the Youth Mental Health Research Program at the BMRI, and Deputy Director of St Vincent’s Private Hospital Young Adult Mental Health Unit. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. IBH is a Commissioner in Australia’s new National Mental Health Commission from 2012. He was a director of headspace: the national youth mental health foundation until January 2012. He was previously the chief executive officer (till 2003) and clinical adviser (till 2006) of beyondblue, an Australian National Depression Initiative. He is the executive director of the Brain and Mind Research Institute, which operates two early-intervention youth services under contract to headspace. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs. He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of non-government organisations and the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). He is a member of the Medical Advisory Panel for Medibank Private and also a Board Member of Psychosis Australia Trust. He leads an investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. The competing interests do not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2015","04","Joanne S Carpenter","JSC",9,TRUE,6,5,1,9,TRUE,TRUE,FALSE,0,NA,FALSE
